The University of Southampton
University of Southampton Institutional Repository

Nedocromil sodium and levocabastine reduce the symptoms of conjunctival allergen challenge by different mechanisms

Nedocromil sodium and levocabastine reduce the symptoms of conjunctival allergen challenge by different mechanisms
Nedocromil sodium and levocabastine reduce the symptoms of conjunctival allergen challenge by different mechanisms
Background: Nedocromil sodium and levocabastine are widely used for the treatment of ocular allergy, but their mechanisms of action are unclear.
Objective: We sought to compare the efficacy and mechanisms of action of nedocromil sodium and levocabastine in reducing conjunctival symptoms after ocular allergen challenge. Methods: We performed a double-blind, placebo-controlled study in which 48 subjects were randomized to 3 groups to receive nedocromil sodium (2%), levocabastine (0.05%), or placebo eye drops twice daily for 2 weeks before ocular challenge with 10 ?L of ryegrass extract. Symptoms and tear histamine and PGD2 concentrations were determined before challenge and at 10, 20, 30, 60, 180, and 360 minutes after challenge. Bulbar biopsy specimens were taken at 6 and 24 hours after challenge to assess conjunctival inflammatory cell numbers, adhesion molecule expression, and mast cell–associated IL-4, IL-5, IL-6, IL-13, and TNF-? levels.
Results: Both drugs significantly reduced total symptom scores (P < .05) at all times after challenge compared with placebo. Itching, hyperemia, and lacrimation were most affected. Nedocromil sodium treatment reduced tear concentrations of histamine (by 77%) and PGD2 (by 70%) at 30 minutes after challenge (both P < .05). In biopsy specimens nedocromil sodium reduced the number of 3H4-positive mast cells (purportedly the secreted form of IL-4) by 49% at 6 hours and 59% at 24 hours (both P < .05). Levocabastine reduced intercellular adhesion molecule 1 expression by 52% at 6 hours and 45% at 24 hours (both P < .05).
Conclusion: Nedocromil sodium and levocabastine both reduced the conjunctival symptoms after ocular allergen challenge but appeared to work by different mechanisms. Nedocromil sodium reduced mast cell function, whereas levocabastine appeared to have primarily antihistaminic actions, although it also reduced the expression of intercellular adhesion molecule 1.
nedocromil sodium, levocabastine, conjunctival challenge, seasonal allergic conjunctivitis, mast cells, histamine, prostaglandin D2, intercellular adhesion molecule 1
0091-6749
449-454
Ahluwalia, Poonam
27eebd5a-7476-4f0f-b495-9a863f43d8ea
Anderson, David F.
de3b2d61-3698-4c8f-adcf-604483666fda
Wilson, Susan J.
21c6875d-6870-441b-ae7a-603562a646b8
McGill, James I.
1a4b2df8-00c4-4923-a13f-cb7340a51749
Church, Martin K.
dad189d5-866e-4ae1-b005-0d87f74282b8
Ahluwalia, Poonam
27eebd5a-7476-4f0f-b495-9a863f43d8ea
Anderson, David F.
de3b2d61-3698-4c8f-adcf-604483666fda
Wilson, Susan J.
21c6875d-6870-441b-ae7a-603562a646b8
McGill, James I.
1a4b2df8-00c4-4923-a13f-cb7340a51749
Church, Martin K.
dad189d5-866e-4ae1-b005-0d87f74282b8

Ahluwalia, Poonam, Anderson, David F., Wilson, Susan J., McGill, James I. and Church, Martin K. (2001) Nedocromil sodium and levocabastine reduce the symptoms of conjunctival allergen challenge by different mechanisms. Journal of Allergy and Clinical Immunology, 108 (3), 449-454. (doi:10.1067/mai.2001.117591).

Record type: Article

Abstract

Background: Nedocromil sodium and levocabastine are widely used for the treatment of ocular allergy, but their mechanisms of action are unclear.
Objective: We sought to compare the efficacy and mechanisms of action of nedocromil sodium and levocabastine in reducing conjunctival symptoms after ocular allergen challenge. Methods: We performed a double-blind, placebo-controlled study in which 48 subjects were randomized to 3 groups to receive nedocromil sodium (2%), levocabastine (0.05%), or placebo eye drops twice daily for 2 weeks before ocular challenge with 10 ?L of ryegrass extract. Symptoms and tear histamine and PGD2 concentrations were determined before challenge and at 10, 20, 30, 60, 180, and 360 minutes after challenge. Bulbar biopsy specimens were taken at 6 and 24 hours after challenge to assess conjunctival inflammatory cell numbers, adhesion molecule expression, and mast cell–associated IL-4, IL-5, IL-6, IL-13, and TNF-? levels.
Results: Both drugs significantly reduced total symptom scores (P < .05) at all times after challenge compared with placebo. Itching, hyperemia, and lacrimation were most affected. Nedocromil sodium treatment reduced tear concentrations of histamine (by 77%) and PGD2 (by 70%) at 30 minutes after challenge (both P < .05). In biopsy specimens nedocromil sodium reduced the number of 3H4-positive mast cells (purportedly the secreted form of IL-4) by 49% at 6 hours and 59% at 24 hours (both P < .05). Levocabastine reduced intercellular adhesion molecule 1 expression by 52% at 6 hours and 45% at 24 hours (both P < .05).
Conclusion: Nedocromil sodium and levocabastine both reduced the conjunctival symptoms after ocular allergen challenge but appeared to work by different mechanisms. Nedocromil sodium reduced mast cell function, whereas levocabastine appeared to have primarily antihistaminic actions, although it also reduced the expression of intercellular adhesion molecule 1.

This record has no associated files available for download.

More information

Published date: 2001
Additional Information: Dermatologic and ocular diseases
Keywords: nedocromil sodium, levocabastine, conjunctival challenge, seasonal allergic conjunctivitis, mast cells, histamine, prostaglandin D2, intercellular adhesion molecule 1

Identifiers

Local EPrints ID: 26899
URI: http://eprints.soton.ac.uk/id/eprint/26899
ISSN: 0091-6749
PURE UUID: cc6d86d3-3056-4dc7-a72d-a26cea360d85
ORCID for Susan J. Wilson: ORCID iD orcid.org/0000-0003-1305-8271

Catalogue record

Date deposited: 25 Apr 2006
Last modified: 15 Mar 2024 07:14

Export record

Altmetrics

Contributors

Author: Poonam Ahluwalia
Author: David F. Anderson
Author: Susan J. Wilson ORCID iD
Author: James I. McGill
Author: Martin K. Church

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×